ZFAND5 Knockout cell line (LN-229)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

ZFAND5 (zinc finger AN1-type containing 5) encodes a zinc finger-containing protein with predicted DNA-binding and zinc ion-binding activities. It is predicted to participate in regulation of processes including fibroblast migration and platelet-derived growth factor receptor signaling and is localized primarily to the cytoplasm. ZFAND5 is relevant to studies of zinc finger protein function, cellular signaling, cell migration, and regulation of gene expression.

Established in 1979, LN-229 is a widely recognized and standard human glioblastoma cell line. The line was isolated from cells taken from a patient presenting with a malignant right frontal parieto-occipital glioblastoma (PubMed: 10416987). LN-229 cells adhere stably in culture, displaying an epithelial-like morphology, and are extensively utilized to study apoptotic pathways, cellular autophagy, and tumor suppressor gene interactions within neuro-oncology. Consequently, LN-229 serves as a premier and robust in vitro platform utilized globally for investigating glioblastoma multiforme (GBM) progression mechanisms, blood-brain barrier penetrating candidate drug screenings, and the evaluation of targeted therapeutic modalities.

Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.